List of Excipients in Branded Drug ORUDIS

Generic Drugs Containing ORUDIS

Company	Ingredient	NDC	Excipient
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	D&C YELLOW NO. 10
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	FD&C BLUE NO. 1
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	GELATIN
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	LACTOSE MONOHYDRATE
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	MAGNESIUM STEARATE
Allegis Pharmaceuticals Inc	ketoprofen	28595-031	POVIDONE K30

What are the Most Frequently-Used Excipients in ORUDIS?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	GELATIN
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POVIDONE K30

# ORUDIS Excipient Strategy and Commercial Opportunities for Ketoprofen Formulations

Last updated: August 28, 2026

Orudis is a historical brand for ketoprofen, a nonsteroidal anti-inflammatory drug used for pain, osteoarthritis, rheumatoid arthritis, and dysmenorrhea. Its commercial value now lies less in reviving the legacy immediate-release capsule and more in developing differentiated ketoprofen products using excipient-controlled release, gastroprotective delivery, topical administration, and patient-friendly dosage forms.

The strongest opportunities are modified-release oral products, low-irritancy topical systems, and 505(b)(2) products that combine ketoprofen with excipients or delivery technologies that improve tolerability, adherence, or dosing convenience. The principal constraints are generic competition, NSAID class warnings, limited willingness to pay for an established active ingredient, and the need to demonstrate meaningful clinical or pharmacokinetic differentiation.

What is Orudis and which ketoprofen formulations were marketed?

Orudis is associated with ketoprofen, an arylpropionic acid NSAID related pharmacologically to ibuprofen and naproxen. Historical U.S. oral products included immediate-release ketoprofen capsules in 25 mg, 50 mg, and 75 mg strengths. Orudis SR was associated with a prolonged-release 200 mg formulation in certain markets.

Product or presentation	Active ingredient	Typical commercial positioning	Excipient and formulation relevance
Orudis capsules	Ketoprofen	Immediate-release oral analgesic and anti-inflammatory	Simple capsule platform; limited differentiation from generic ketoprofen
Orudis SR	Ketoprofen	Once-daily or extended-duration treatment	Matrix or multiparticulate release system; higher formulation value
Ketoprofen topical gel	Ketoprofen	Local pain treatment with lower systemic exposure	Solubilization, permeation enhancement, rheology, and skin tolerability
Ketoprofen lysine or other salt products	Ketoprofen salt	Faster dissolution or alternative regional product	Salt selection, pH control, taste, and moisture management
Ketoprofen combination products	Ketoprofen plus another active	Analgesic or gastroprotective positioning	Compatibility, dose uniformity, release separation, and regulatory complexity

FDA labeling for ketoprofen identifies standard oral dosage forms and class-wide NSAID warnings, including gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, and hypersensitivity reactions (FDA, 2023a; FDA, 2023b).

What excipients were used in legacy Orudis capsules?

Legacy immediate-release Orudis capsules used conventional oral excipients. Public product labeling identifies excipient categories including lactose, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate, with gelatin capsule shells and colorants varying by strength or market presentation (DailyMed, n.d.).

The formulation strategy was functional rather than differentiated:

• Lactose acted primarily as a diluent.
• Magnesium stearate provided lubrication.
• Colloidal silicon dioxide improved powder flow.
• Sodium lauryl sulfate supported wetting and dispersion.
• Gelatin provided the capsule shell.
• Titanium dioxide and colorants supported product identification.

This excipient system is inexpensive and scalable but offers limited protection against generic substitution. A modern product would need a measurable advantage in release profile, gastric exposure, adherence, tolerability, or route of administration.

What excipient risks affect ketoprofen capsules?

Ketoprofen is a relatively lipophilic weak acid with dissolution behavior affected by particle size, pH, wetting, and solid-state properties. The main development risks are:

1. Inconsistent dissolution caused by poor wetting or agglomeration.
2. Sensitivity to lubricant concentration and blending time.
3. Capsule-fill variability at low dose strengths.
4. Lactose intolerance or excipient avoidance in selected patient populations.
5. Gastric irritation that is intrinsic to NSAID therapy and cannot be eliminated through excipient selection alone.
6. Food effects that alter the rate of absorption.
7. Dose dumping if a modified-release coating or matrix fails under gastrointestinal conditions.

A lactose-free, low-moisture, direct-compression or liquid-filled hard-capsule platform could improve manufacturing flexibility and expand use among patients who avoid lactose. That change alone would have weak commercial value unless paired with a clinically relevant performance claim.

What excipient strategy is strongest for an Orudis reformulation?

The strongest strategy is a platform-based approach that links excipient selection to a commercial claim. A reformulation should not rely on an inactive-ingredient change without a clear benefit.

Development objective	Excipient or technology direction	Potential commercial claim	Principal technical risk
Faster onset	Micronized ketoprofen, wetting agents, surfactants, fast-disintegrating systems	Earlier pain relief	Increased local gastric exposure and variable absorption
Extended release	Hydrophilic matrix polymers, insoluble polymers, multiparticulates	Less frequent dosing	Dose dumping and food-dependent release
Reduced gastric exposure	Enteric coating, delayed release, gastroretentive design	Improved upper-gastrointestinal tolerability	Delayed onset and limited ability to prevent systemic NSAID toxicity
Topical delivery	Ethanol, propylene glycol, glycols, phospholipids, permeation enhancers, carbomers	Local treatment with lower systemic exposure	Skin irritation and variable penetration
Improved swallowability	Smaller capsules, orally disintegrating tablets, granules, taste-masked multiparticulates	Easier administration	Bitter taste and dose uniformity
Lower excipient burden	Co-processed excipients and optimized particle engineering	Clean-label or simplified formulation	Weak regulatory differentiation
Combination protection	Bilayer or dual-release dosage form with gastroprotective agent	NSAID treatment with acid suppression	Drug-drug interaction, complex bioequivalence, additional safety obligations

Is enteric coating a commercially viable Orudis strategy?

Enteric coating can reduce release in the stomach, but it does not remove the systemic cardiovascular, renal, or gastrointestinal risks associated with ketoprofen. Clinical and regulatory claims must therefore remain narrow. A delayed-release product may be positioned around dosing-site control or a specific pharmacokinetic profile, but "gastroprotective" positioning would require clinical evidence.

Suitable coating systems include methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, and related pH-dependent polymers. The selection must account for coating weight gain, dissolution thresholds, storage stability, and the impact of food.

Can a gastroprotective ketoprofen product create value?

A ketoprofen product combined with a proton-pump inhibitor or another gastroprotective agent could target patients requiring continued NSAID therapy. The commercial precedent is the NSAID-plus-proton-pump-inhibitor category, including naproxen/esomeprazole products.

The opportunity has meaningful clinical logic but high execution risk. A ketoprofen combination would need to establish:

• Dose selection for both components.
• Release compatibility.
• Absorption comparability.
• Long-term safety.
• Adherence improvement over separate tablets.
• A differentiated indication or patient population.

A fixed-dose combination could support a 505(b)(2) strategy if the reference product and bridging evidence are suitable. It would still face competition from low-cost generic ketoprofen plus generic proton-pump inhibitors.

What are the best commercial opportunities for Orudis today?

1. Extended-release ketoprofen

An extended-release product has the clearest oral differentiation. Once-daily dosing can improve adherence for chronic osteoarthritis or rheumatoid arthritis patients. A multiparticulate capsule may provide better control than a single hydrophilic matrix because it can reduce the risk that one damaged unit releases the entire dose.

Potential excipient systems include:

• Hypromellose matrices.
• Ethylcellulose-coated pellets.
• Ammonio methacrylate copolymers.
• Microcrystalline cellulose pellet cores.
• Povidone or hydroxypropyl cellulose binders.
• pH-independent release coatings.

The product would need a reproducible pharmacokinetic profile and a clinically credible dosing advantage. The commercial ceiling remains moderate because generic extended-release NSAIDs and other once-daily NSAIDs already compete in the market.

2. Topical ketoprofen

Topical ketoprofen is a more attractive route-specific opportunity than a simple oral reformulation. It can target localized musculoskeletal pain while reducing systemic exposure relative to oral administration, although systemic absorption and NSAID-related risks remain relevant.

Excipient development should focus on:

• Ketoprofen solubilization.
• Skin partitioning.
• Controlled permeation.
• Rapid drying.
• Non-greasy sensory profile.
• Low irritation.
• Stability under heat and light.

A hydroalcoholic gel, emulgel, foam, spray, or film-forming solution could support differentiated consumer positioning. Carbomer or acrylate rheology modifiers can provide gel structure. Ethanol and propylene glycol can improve solubilization and permeation but may cause dryness or irritation. Liposomal, microemulsion, and nanostructured lipid systems may improve delivery, but their manufacturing complexity must be justified by superior performance.

Topical ketoprofen has a specific regulatory issue: photosensitivity and photoallergic reactions have been reported with topical ketoprofen in some markets. Product design, labeling, packaging, and post-market surveillance must address ultraviolet exposure and dermatologic risk (European Medicines Agency, 2011).

3. Orally disintegrating or multiparticulate products

An orally disintegrating tablet or sachet could target older patients with dysphagia and patients who prefer administration without water. The formulation challenge is ketoprofen's taste and the need to maintain dose uniformity at relatively high drug loads.

Useful approaches include:

• Ion-exchange resin taste masking.
• Polymer coating of drug particles.
• Lipid-based taste barriers.
• Effervescent granules.
• Orally disintegrating mini-tablets.
• Single-dose powder sachets.

The opportunity is commercially attractive only if the product improves adherence or access. An orally disintegrating product with no meaningful taste or onset advantage would face rapid generic substitution.

How does Orudis compare with competing NSAID products?

Product category	Competitive advantage	Excipient opportunity for ketoprofen	Commercial pressure
Ibuprofen immediate release	Low cost and high consumer recognition	Faster onset or better tolerability	Very high
Naproxen	Longer duration and established OTC presence	Extended-release or topical delivery	High
Celecoxib	COX-2 selectivity and prescription positioning	Gastroprotective or targeted-release product	High
Diclofenac topical	Strong topical brand and generic presence	Better skin tolerability or delivery efficiency	High
Ketoprofen topical	Established regional use	Improved sensory profile and photoprotection labeling	Moderate to high
Acetaminophen	Non-NSAID analgesic positioning	Anti-inflammatory differentiation	High

Ketoprofen's main differentiation is not low cost. It must compete through route, dosing frequency, onset, patient acceptability, or a targeted clinical population.

What is the FDA regulatory status and Orange Book position of Orudis?

Orudis is not a strong current U.S. brand platform. Historical Orudis products have faced generic competition, and the commercial relevance of the brand depends on the status of the applicable NDA and marketed presentations.

The FDA Orange Book distinguishes active products from discontinued products and identifies listed patents and exclusivity associated with approved applications. A discontinued product listing does not by itself establish a safety withdrawal or eliminate the possibility of development under a different application pathway (FDA, n.d.-a).

For a new ketoprofen product, the likely regulatory routes are:

• Abbreviated New Drug Application for a conventional generic equivalent.
• 505(b)(2) application for a new dosage form, route, salt, formulation, or combination.
• New drug application if the sponsor seeks substantial clinical differentiation.
• Regional non-U.S. pathways for topical or modified-release products where ketoprofen remains marketed.

A new excipient is not automatically patentable or regulatory differentiating. The sponsor must show that the formulation produces a meaningful and reproducible product attribute.

What patents protect Orudis and are Paragraph IV challenges relevant?

The original Orudis composition and product patents are unlikely to provide a durable U.S. exclusivity barrier for a new entrant. Any historical patents covering ketoprofen, conventional capsules, or early sustained-release designs should be evaluated against their expiration dates and prosecution history before investment.

Paragraph IV risk is relevant mainly when a sponsor files an ANDA referencing an active listed product with Orange Book patents. For a discontinued brand, the practical analysis depends on whether the reference product remains eligible for ANDA reliance, whether an approved generic product exists, and whether listed patents remain active.

A 505(b)(2) sponsor faces a different patent analysis. Relevant risks include:

• Formulation patents covering polymer matrices or coated pellets.
• Topical delivery patents covering permeation enhancers or lipid carriers.
• Combination patents covering ketoprofen plus gastroprotective agents.
• Method-of-use patents directed to specific pain populations.
• Manufacturing patents covering particle engineering or coating processes.

Patent strength is likely to be moderate for a genuinely differentiated delivery system and weak for simple excipient substitutions. Broad claims directed only to "ketoprofen plus a conventional diluent" are vulnerable to validity and obviousness challenges. Narrow claims tied to dissolution profiles, particle-size distributions, coating parameters, or clinical pharmacokinetics may have stronger enforcement value if supported by the specification.

Which companies could challenge or compete with a new Orudis product?

Competition would come from several groups:

1. Generic manufacturers of ketoprofen capsules and tablets.
2. Regional manufacturers of topical ketoprofen gels and patches.
3. Large OTC companies selling ibuprofen and naproxen.
4. Specialty pharmaceutical companies developing topical analgesic systems.
5. Contract development and manufacturing organizations with multiparticulate or transdermal capabilities.
6. Sponsors of NSAID and gastroprotective fixed-dose combinations.

The most credible generic challenge would target price and supply reliability. A differentiated product would need to create a separate market segment rather than compete solely on active-ingredient identity.

What manufacturing and intellectual-property barriers affect commercialization?

Manufacturing barriers are manageable for immediate-release capsules but increase sharply for advanced delivery systems.

Oral modified release

Key controls include pellet size, coating weight gain, polymer permeability, residual solvent levels, dissolution at multiple pH conditions, and stability under humidity. Scale-up can alter coating uniformity and release kinetics.

Topical systems

Manufacturing must control drug crystallization, viscosity, particle size, homogeneity, preservative performance, and container compatibility. Pump, tube, and airless packaging can affect dose delivery and product stability.

Intellectual property

A defensible estate could include:

• Composition claims for a defined excipient system.
• Process claims for drug particle engineering.
• Dosage-form claims tied to release parameters.
• Packaging claims that limit light or oxygen exposure.
• Method claims covering a specific patient group or dosing schedule.
• Manufacturing controls that produce a clinically relevant dissolution profile.

Trade-secret protection may be more valuable than patents for process parameters, coating conditions, and scale-up methods.

How much revenue exposure exists for a new ketoprofen product?

A conventional oral ketoprofen generic would have limited revenue potential because of established substitution and low pricing. A topical or modified-release product could command a premium, but the addressable market would depend on route-specific prescribing, reimbursement, and the availability of competing NSAIDs.

Product strategy	Revenue potential	Development complexity	Expected market access
Standard ketoprofen capsule	Low	Low	Generic pricing
Lactose-free capsule	Low to moderate	Low	Niche differentiation
Extended-release capsule	Moderate	Moderate to high	Prescription or regional
Topical gel or emulgel	Moderate to high	Moderate	Consumer, OTC, or prescription depending on jurisdiction
Ketoprofen plus gastroprotective agent	Moderate	High	Specialist and chronic-use segment
Orally disintegrating product	Low to moderate	Moderate	Adherence-focused niche
Novel transdermal system	High potential, high risk	High	Requires strong clinical and regulatory package

The most investable profile is a topical ketoprofen product with a superior sensory profile and validated delivery performance, or an extended-release product with a clear once-daily adherence advantage.

Key Takeaways

• Orudis is a historical ketoprofen brand with limited standalone U.S. brand equity.
• Conventional capsule excipients offer little commercial or patent differentiation.
• Extended-release oral delivery is the strongest oral reformulation opportunity.
• Topical ketoprofen provides the best route-based opportunity, subject to photosensitivity and skin-tolerability controls.
• Enteric coating may alter release location but does not eliminate systemic NSAID risks.
• A gastroprotective combination could support a 505(b)(2) strategy but would require substantial development and safety evidence.
• Simple excipient substitution is unlikely to support meaningful pricing power or enforceable patent protection.
• The strongest intellectual-property position would combine composition, process, dissolution, packaging, and method-of-use claims.
• Generic competition makes a standard Orudis capsule commercially unattractive without a material formulation advantage.

Frequently Asked Questions

Is Orudis still available in the United States?

Orudis has limited current U.S. commercial significance compared with generic ketoprofen products. FDA Orange Book and product-label records should be used to confirm the status of each historical NDA and presentation.

Can ketoprofen be reformulated as an over-the-counter product?

A topical ketoprofen product may have an OTC opportunity in selected jurisdictions, but U.S. OTC approval would require compliance with the applicable FDA monograph or an NDA pathway. Oral OTC approval would involve broader safety and labeling considerations.

Does a topical ketoprofen gel avoid NSAID cardiovascular risk?

No. Topical administration may reduce systemic exposure compared with oral dosing, but it does not eliminate systemic absorption or class-related NSAID risks.

What is the best excipient for extended-release ketoprofen?

No single excipient is universally optimal. Hydrophilic matrices, ethylcellulose coatings, and methacrylate polymers are leading platform options. The final selection depends on the target dissolution profile, dose, food effect, manufacturing process, and bioequivalence strategy.

Can a ketoprofen formulation receive new patent protection after the original Orudis patents expire?

Yes. New patents may protect a novel formulation, delivery system, manufacturing process, dosage regimen, or combination. The claims must provide novelty and non-obviousness beyond the historical Orudis formulation.

References

1. DailyMed. (n.d.). Orudis- ketoprofen capsule labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. European Medicines Agency. (2011). Ketoprofen-containing topical products: European review of photosensitivity risk. https://www.ema.europa.eu/

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2023a). Ketoprofen prescribing information. FDA. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (2023b). Nonsteroidal anti-inflammatory drugs: Drug safety communication. FDA. https://www.fda.gov/Drugs/DrugSafety/